Back to News
Market Impact: 0.25
KORTUC Achieves Target Enrollment in Registrational Breast Cancer Trial as Three Global Clinical Programs Advance
Source: GlobeNewswire
Healthcare & BiotechCorporate Guidance & Outlook
KORTUC reached 184 enrolled patients in its lead clinical program, advancing the study toward a planned readout. The company is also progressing a cervical-cancer study with UC San Diego and received authorization for its K-BOOST rectal program, expanding its clinical development pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Nasdaq futures sink 2.3% as Amazon, Intel and Alphabet send AI jitters through stocks
- Samsung hosts OpenAI’s Altman for talks on AI chips and infrastructure
- Why is iShares Semiconductor ETF plunging today?